BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Mechanism of Action
BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels.
Dosage Overview
Dose Range
250 mcg – 500 mcg
Route
subcutaneous
Frequency
2x daily
Cycle Length
4–6 weeks
Reconstitution
Typical Dosage (Research)
Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied.
Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable.
Considerations for Men & Women
Women: No established sex-specific differences in healing or anti-inflammatory effects. Some anecdotal reports of temporary changes in menstrual flow or timing during use, though no controlled studies confirm this. Standard dosing applies.
Men: No established sex-specific differences. Standard dosing and protocols apply equally.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Concentration: 2.5 mg/ml
Volume to inject: 0.10 ml
Syringe units (U-100): 10.0 units
Pre-filled with BPC-157 defaults. Adjust values as needed.
Side Effects & Risks
Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses.
Limited human clinical trial data. Long-term effects not well established. Not FDA approved for human use.
Who Uses BPC-157
Athletes recovering from injuries, individuals with tendon or ligament issues, those seeking gut health support.
Frequently Asked Questions
Similar Peptides
View All Alternatives →IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.